|
Patent landscape, scope, and claims summary: |
US Patent 10,369,210 (Influenza Virus Production Using Host-Genome Suppression in HEK293/Vero/MDCK Cells): Claim-by-Claim Analysis and US Patent Landscape
US Patent 10,369,210 claims methods for producing influenza virus by infecting cultured cells (HEK293, Vero, or MDCK) whose chromosomal gene expression is suppressed via deletion/disruption, siRNA, or CRISPR/Cas targeting a defined list of host genes (e.g., ACTG1, ACTN1, CCT6A, COPS7B, DAP3, ERLIN2, GNAI2, GTF3C5, HNRPAB, KHSRP, KRT18, MTCH1, PPP2R1A, PRPS1, RAB18, RAB3A, RAP1B, RPS19, RPS7, S100A10, SFRS7, SLC2A12, TMED2, USP10). Claims also tie the produced virus to influenza vaccine formulation.
What do the claims of US 10,369,210 actually cover?
Core claim concept (Claim 1). A method for producing influenza virus using cell lines that are genetically or functionally modified to suppress expression of one or more specified chromosomal genes, followed by influenza infection and culturing infected cells.
Claim scope gates:
- Influenza virus production: requires infecting cells and culturing infected cells to produce virus.
- Permitted host cell lines: HEK293, Vero, MDCK only.
- Host gene suppression must use the listed genes: ACTG1, ACTN1, CCT6A, COPS7B, DAP3, ERLIN2, GNAI2, GTF3C5, HNRPAB, KHSRP, KRT18, MTCH1, PPP2R1A, PRPS1, RAB18, RAB3A, RAP1B, RPS19, RPS7, S100A10, SFRS7, SLC2A12, TMED2, USP10 (and narrowing sets in dependent claims).
- Suppression mechanism is broad in Claim 1: “expression suppressed,” with dependent claims narrowing to deleted/disrupted, siRNA, or CRISPR/Cas.
Claim-by-claim compression (what each one adds)
| Claim |
Added limitation vs. Claim 1 |
Practical effect on infringement risk |
| 1 |
Base method; HEK293/Vero/MDCK; expression suppressed for a listed host gene set |
Biggest scope; broadest infringement surface |
| 2 |
Virus formulated into influenza vaccine |
Narrows to downstream vaccine formulation; may reduce direct infringement by a manufacturer that only makes bulk virus |
| 3 |
Chromosomal gene deleted or disrupted |
Narrows from any suppression approach to stable genomic disruption |
| 4 |
Limits host genes to a subset (ACTG1, ACTN1, DAP3, GNAI2, GTF3C5, KRT18, MTCH1, PRPS1, RPS19, S100A10, S100A10, SFRS7, SLC2A12, USP10, PPP2R1A, TMED2) |
Medium-narrow; still large enough to capture multiple targets |
| 5 |
Cells are HEK293 |
Narrows host; only relevant to HEK293-based manufacturing |
| 6 |
Adds siRNA introduction before infecting |
Converts “suppressed expression” into RNAi workflow |
| 7 |
Cells are Vero |
Narrows host |
| 8 |
Limits gene subset for Vero |
Narrows further; may dodge if different targets are used |
| 9 |
Adds siRNA step |
Adds operational specificity |
| 10 |
Cells are MDCK |
Narrows host |
| 11 |
Gene subset for MDCK (KRT18, PPP2R1A, TMED2, USP10) |
Strong narrowing; only those genes land |
| 12 |
Adds siRNA step |
Adds operational specificity for MDCK |
| 13 |
Limits MDCK genes further (KRT18 and/or USP10) |
Tightest within MDCK/siRNA family short of CRISPR |
| 14 |
Adds CRISPR/Cas with guide RNA prior to infecting |
Tightest operational method: genome editing workflow |
How strong is the patent’s coverage: claim construction and enforceability levers
“Expression suppressed” is the main battleground
Claim 1 uses “expression of at least one chromosomal gene is suppressed.” That phrase is typically construed broadly enough to encompass:
- siRNA knockdown (later explicitly claimed)
- CRISPR/Cas disruption (later explicitly claimed)
- deletion/disruption (Claim 3)
- potentially other suppression modalities, depending on prosecution history and specification support
From an infringement standpoint, Claim 1’s breadth increases if any legitimate influenza upstream process uses engineered HEK293/Vero/MDCK with one or more listed genes knocked down or functionally silenced (even if the platform is described as “host factor knockout” or “host antiviral pathway modulation,” so long as the target gene expression is reduced).
From a validity standpoint, broad functional language can also draw prior-art pressure if earlier influenza manufacturing papers or patents used gene suppression in general, even if not with the same gene list.
The gene list makes this a “targeted host engineering” patent, not a generic gene-suppression patent
Unlike broad “reduce host factors to increase virus yield,” Claim 1 is constrained to a named set of host genes. That reduces prior-art overlap for generic RNAi/CRISPR influenza production, but it raises the question of whether prior patents taught the same specific host genes for influenza production.
The claim set is structured like an offense in layers
The patent is engineered so that:
- Claim 1 captures the generic concept (host suppression + influenza infection/culture) on three common cell substrates.
- dependent claims capture common implementation routes: siRNA and CRISPR.
- additional dependent claims narrow gene subsets by cell line, indicating the inventors likely identified gene-by-cell-line performance.
This “platform + implementation + target list” structure tends to support both:
- injunctive theories against platform users using the same host targets, and
- design-around pressure (changing cell line, changing targeted genes, or changing suppression mechanism).
What patents likely intersect the landscape for US 10,369,210?
Without a verified bibliographic record (publication number, assignee, filing date, and specification disclosure), it is not possible to produce a complete, accurate map of:
- family members
- prosecution history
- examiner-cited prior art
- specific US “close competitors” in the same claim space
- whether US 10,369,210 is an improvement over earlier host-engineering patents or a later filing on a narrow target list
Because the prompt requires a comprehensive, critical analysis grounded in patent numbers and litigation-ready intersections, no complete landscape can be produced from the claim text alone without risking factual errors.
Key infringement scenarios under US 10,369,210
Direct infringement risk (method steps all performed by one entity)
Infringement is most likely where a single party:
- uses HEK293/Vero/MDCK,
- applies siRNA or CRISPR (or stable deletion/disruption) to suppress one of the listed genes,
- infects with influenza virus,
- cultures infected cells to produce virus,
- and in some theories, formulates the resulting virus into a vaccine (Claim 2).
Joint infringement / divided performance risk
If host engineering is done by one vendor (cell engineering) and infection/culture is done by another (manufacturing), enforcement will turn on whether the law in the relevant jurisdiction supports a “single actor” theory or whether inducement/contribution is pleaded. The claim text itself does not resolve that.
Design-around levers
To avoid the claims, an operator would generally need to change at least one of:
- cell line (use a different permitted substrate),
- the targeted host gene(s) (avoid the listed genes),
- the suppression mechanism if the design-around routes fall outside Claim 1’s “expression suppressed” scope (but Claims 3, 6, 9, 12, 14 separately cover disruption/siRNA/CRISPR, so relying on a different suppression mechanism still must avoid the functional language of Claim 1).
Patent strength assessment: what would make this patent enforceable?
From the claim drafting alone, the patent’s enforceability typically depends on:
- whether the specification supports each gene and each modality (siRNA, CRISPR, deletion/disruption) on each cell line
- whether the inventor’s experimental results tied those genes to influenza virus production
- whether the gene list is sufficiently novel compared with earlier host factor influenza literature
- whether the claims were narrowed during prosecution to overcome prior art
Claim architecture suggests the patent is meant to be enforceable across multiple gene targets and multiple genome-suppression technologies.
What generic or competitor entry risks exist for influenza vaccine manufacturing?
For influenza vaccine production on engineered cell lines, risk centers on whether the competitor’s platform:
- uses HEK293, Vero, or MDCK,
- performs host genome suppression of one of the listed genes,
- produces virus via infection/culture in a way that matches the claims.
If a competitor uses a different host factor panel or edits different genes, this patent’s coverage narrows quickly because Claim 1 is gene-list constrained.
Key takeaways
- US 10,369,210 is a targeted host-engineering patent: it claims influenza virus production in HEK293, Vero, and MDCK cells with suppression of specific listed chromosomal genes.
- The claim set is layered: Claim 1 is the broadest (functional suppression + infection/culture), while dependent claims narrow to vaccine formulation and to siRNA, gene deletion/disruption, or CRISPR/Cas approaches, often with cell line-specific gene subsets.
- The main infringement battleground is whether an alleged process suppresses expression of any listed host gene in the permitted cell lines before influenza infection.
- The main invalidity battleground is novelty/obviousness against prior host-factor influenza manufacturing work, which would need a verified prior-art record to assess properly.
- A credible design-around requires changing at least one claim pillar: cell line, target genes, or the manner in which “expression suppressed” is achieved.
FAQs
1. Does US 10,369,210 require CRISPR to be infringed?
No. CRISPR is only expressly recited in Claim 14. Claim 1 covers “expression suppressed,” and dependent claims add specific mechanisms like siRNA (Claims 6, 9, 12) and deletion/disruption (Claim 3).
2. If a company knocks out a listed gene but uses a different cell line, does this patent apply?
Claim 1 is limited to HEK293, Vero, or MDCK. Using other cell lines avoids the express cell-line limitation.
3. Is vaccine formulation required for infringement?
No. Claim 2 adds vaccine formulation, but Claim 1 covers influenza virus production before formulation.
4. What host genes are most limiting for MDCK-based processes in this patent?
Within the MDCK family, Claims 11 to 13 narrow the gene set to KRT18, PPP2R1A, TMED2, USP10, and further to KRT18 and/or USP10 in Claim 13.
5. Could a process that reduces gene expression without siRNA or CRISPR still fall under Claim 1?
Claim 1 uses the functional language “expression … is suppressed,” so alternative suppression approaches could still fall within Claim 1 if they suppress the listed genes in the permitted cell lines.
References
- United States Patent 10,369,210. (Claims as provided in user prompt).
More… ↓
⤷ Start Trial
|
